The popularity of Sildenafil initially sparked a surge for the drug industry, but recent developments present a complicated picture for shareholders. Off-patent competitors are eroding profits, and persistent patent challenges add further risk to the equation. While some companies could still gain from complementary products, the overall trend sugg